Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

Phage Display-Based Nanotechnology Applications in Cancer Immunotherapy.

Goracci M, Pignochino Y, Marchiò S.

Molecules. 2020 Feb 14;25(4). pii: E843. doi: 10.3390/molecules25040843. Review.

2.

A Functional Idiotype/Anti-Idiotype Network Is Active in Genetically Gluten-Intolerant Individuals Negative for Both Celiac Disease-Related Intestinal Damage and Serum Autoantibodies.

Quaglia S, Ferrara F, De Leo L, Ziberna F, Vatta S, Marchiò S, Sblattero D, Ventura A, Not T.

J Immunol. 2019 Feb 15;202(4):1079-1087. doi: 10.4049/jimmunol.1800819. Epub 2019 Jan 11.

3.

Anti-GRP78 autoantibodies induce endothelial cell activation and accelerate the development of atherosclerotic lesions.

Crane ED, Al-Hashimi AA, Chen J, Lynn EG, Won KD, Lhoták Š, Naeim M, Platko K, Lebeau P, Byun JH, Shayegan B, Krepinsky JC, Rayner KJ, Marchiò S, Pasqualini R, Arap W, Austin RC.

JCI Insight. 2018 Dec 20;3(24). pii: 99363. doi: 10.1172/jci.insight.99363.

4.

Emerging Pharmacologic Targets in Cerebral Cavernous Malformation and Potential Strategies to Alter the Natural History of a Difficult Disease: A Review.

Chohan MO, Marchiò S, Morrison LA, Sidman RL, Cavenee WK, Dejana E, Yonas H, Pasqualini R, Arap W.

JAMA Neurol. 2019 Apr 1;76(4):492-500. doi: 10.1001/jamaneurol.2018.3634. Review.

PMID:
30476961
5.

Autoantibodies against the cell surface-associated chaperone GRP78 stimulate tumor growth via tissue factor.

Al-Hashimi AA, Lebeau P, Majeed F, Polena E, Lhotak Š, Collins CAF, Pinthus JH, Gonzalez-Gronow M, Hoogenes J, Pizzo SV, Crowther M, Kapoor A, Rak J, Gyulay G, D'Angelo S, Marchiò S, Pasqualini R, Arap W, Shayegan B, Austin RC.

J Biol Chem. 2017 Dec 22;292(51):21180-21192. doi: 10.1074/jbc.M117.799908. Epub 2017 Oct 24.

6.

Going viral? Linking the etiology of human prostate cancer to the PCA3 long noncoding RNA and oncogenic viruses.

Teixeira AA, Marchiò S, Dias-Neto E, Nunes DN, da Silva IT, Chackerian B, Barry M, Lauer RC, Giordano RJ, Sidman RL, Wheeler CM, Cavenee WK, Pasqualini R, Arap W.

EMBO Mol Med. 2017 Oct;9(10):1327-1330. doi: 10.15252/emmm.201708072. No abstract available.

7.

BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation.

Lewis VO, Devarajan E, Cardó-Vila M, Thomas DG, Kleinerman ES, Marchiò S, Sidman RL, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):8065-8070. doi: 10.1073/pnas.1704173114. Epub 2017 Jul 11.

8.

Intracellular targeting of annexin A2 inhibits tumor cell adhesion, migration, and in vivo grafting.

Staquicini DI, Rangel R, Guzman-Rojas L, Staquicini FI, Dobroff AS, Tarleton CA, Ozbun MA, Kolonin MG, Gelovani JG, Marchiò S, Sidman RL, Hajjar KA, Arap W, Pasqualini R.

Sci Rep. 2017 Jun 26;7(1):4243. doi: 10.1038/s41598-017-03470-w.

9.

Interaction between Tumor Cell Surface Receptor RAGE and Proteinase 3 Mediates Prostate Cancer Metastasis to Bone.

Kolonin MG, Sergeeva A, Staquicini DI, Smith TL, Tarleton CA, Molldrem JJ, Sidman RL, Marchiò S, Pasqualini R, Arap W.

Cancer Res. 2017 Jun 15;77(12):3144-3150. doi: 10.1158/0008-5472.CAN-16-0708. Epub 2017 Apr 20.

10.

An antivascular vaccine to boost self-immunity and strike the tumor.

Marchiò S, Bansal P, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):E3164-E3165. doi: 10.1073/pnas.1701452114. Epub 2017 Apr 11. No abstract available.

11.

Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer.

Ferrara F, Staquicini DI, Driessen WHP, D'Angelo S, Dobroff AS, Barry M, Lomo LC, Staquicini FI, Cardó-Vila M, Soghomonyan S, Alauddin MM, Flores LG 2nd, Arap MA, Lauer RC, Mathew P, Efstathiou E, Aparicio AM, Troncoso P, Navone NM, Logothetis CJ, Marchiò S, Gelovani JG, Sidman RL, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12786-12791. doi: 10.1073/pnas.1615400113. Epub 2016 Oct 24.

12.

Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes.

Dobroff AS, D'Angelo S, Eckhardt BL, Ferrara F, Staquicini DI, Cardó-Vila M, Staquicini FI, Nunes DN, Kim K, Driessen WHP, Hajitou A, Lomo LC, Barry M, Krishnamurthy S, Sahin A, Woodward WA, Prossnitz ER, Anderson RL, Dias-Neto E, Brown-Glaberman UA, Royce ME, Ueno NT, Cristofanilli M, Hortobagyi GN, Marchiò S, Gelovani JG, Sidman RL, Arap W, Pasqualini R.

Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12780-12785. doi: 10.1073/pnas.1615288113. Epub 2016 Oct 24.

13.

Interleukin-11 Receptor Is a Candidate Target for Ligand-Directed Therapy in Lung Cancer: Analysis of Clinical Samples and BMTP-11 Preclinical Activity.

Cardó-Vila M, Marchiò S, Sato M, Staquicini FI, Smith TL, Bronk JK, Yin G, Zurita AJ, Sun M, Behrens C, Sidman RL, Lee JJ, Hong WK, Wistuba II, Arap W, Pasqualini R.

Am J Pathol. 2016 Aug;186(8):2162-2170. doi: 10.1016/j.ajpath.2016.04.013. Epub 2016 Jun 16.

14.

Brain endothelial cell-targeted gene therapy of neurovascular disorders.

Marchiò S, Sidman RL, Arap W, Pasqualini R.

EMBO Mol Med. 2016 Jun 1;8(6):592-4. doi: 10.15252/emmm.201606407. Print 2016 Jun. No abstract available.

15.

BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer.

Bartolini A, Cardaci S, Lamba S, Oddo D, Marchiò C, Cassoni P, Amoreo CA, Corti G, Testori A, Bussolino F, Pasqualini R, Arap W, Corà D, Di Nicolantonio F, Marchiò S.

Clin Cancer Res. 2016 Oct 1;22(19):4923-4933. Epub 2016 May 3.

16.

Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumors.

Dondossola E, Dobroff AS, Marchiò S, Cardó-Vila M, Hosoya H, Libutti SK, Corti A, Sidman RL, Arap W, Pasqualini R.

Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2223-8. doi: 10.1073/pnas.1525697113. Epub 2016 Feb 8.

17.

Ligand-targeted theranostic nanomedicines against cancer.

Yao VJ, D'Angelo S, Butler KS, Theron C, Smith TL, Marchiò S, Gelovani JG, Sidman RL, Dobroff AS, Brinker CJ, Bradbury ARM, Arap W, Pasqualini R.

J Control Release. 2016 Oct 28;240:267-286. doi: 10.1016/j.jconrel.2016.01.002. Epub 2016 Jan 6. Review.

18.

The Neuronal Pentraxin-2 Pathway Is an Unrecognized Target in Human Neuroblastoma, Which Also Offers Prognostic Value in Patients.

Bartolini A, Di Paolo D, Noghero A, Murgia D, Sementa AR, Cilli M, Pasqualini R, Arap W, Bussolino F, Ponzoni M, Pastorino F, Marchiò S.

Cancer Res. 2015 Oct 15;75(20):4265-71. doi: 10.1158/0008-5472.CAN-15-0649. Epub 2015 Aug 20.

19.

Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion.

Cossu I, Bottoni G, Loi M, Emionite L, Bartolini A, Di Paolo D, Brignole C, Piaggio F, Perri P, Sacchi A, Curnis F, Gagliani MC, Bruno S, Marini C, Gori A, Longhi R, Murgia D, Sementa AR, Cilli M, Tacchetti C, Corti A, Sambuceti G, Marchiò S, Ponzoni M, Pastorino F.

Biomaterials. 2015 Nov;68:89-99. doi: 10.1016/j.biomaterials.2015.07.054. Epub 2015 Aug 1.

20.

PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3.

Salameh A, Lee AK, Cardó-Vila M, Nunes DN, Efstathiou E, Staquicini FI, Dobroff AS, Marchiò S, Navone NM, Hosoya H, Lauer RC, Wen S, Salmeron CC, Hoang A, Newsham I, Lima LA, Carraro DM, Oliviero S, Kolonin MG, Sidman RL, Do KA, Troncoso P, Logothetis CJ, Brentani RR, Calin GA, Cavenee WK, Dias-Neto E, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8403-8. doi: 10.1073/pnas.1507882112. Epub 2015 Jun 15.

Supplemental Content

Loading ...
Support Center